Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2

PLoS Computational Biology

Volumn 11, Issue 6, 2015, Pages

  Bueren Calabuig, Juan A ^a   Michel, Julien ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFORMATIONS; FREE ENERGY; MOLECULAR DYNAMICS; MOLECULES; ORDER DISORDER TRANSITIONS; PROTEINS;

ACCELERATED MOLECULAR DYNAMICS; BIOMOLECULAR INTERACTIONS; CONFORMATIONAL ENSEMBLE; DISORDER-ORDER TRANSITIONS; DISORDERED PROTEINS; N-TERMINAL DOMAINS; ONCOPROTEINS; RATIONAL DRUG DESIGNS; SMALL MOLECULES; UMBRELLA SAMPLING;

LIGANDS;

1,4 BENZODIAZEPINE 2,5 DIONE; NUTLIN 3; P53 TAD; PIPERIDINONE 2; PROTEIN INHIBITOR; PROTEIN MDM2; UNCLASSIFIED DRUG; LIGAND; MDM2 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DISORDER ORDER TRANSITION; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DYNAMICS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; STRUCTURE ANALYSIS; CHEMICAL PHENOMENA; CHEMISTRY; HUMAN; METABOLISM;

HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940467577     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004282     Document Type: Article

References (80)

1. Habchi J, Tompa P, Longhi S, Uversky VN, (2014) Introducing protein intrinsic disorder. Chem Rev 114: 6561–6588. doi: 10.1021/cr400514h 24739139
2. Uversky VN, (2011) Intrinsically disordered proteins from A to Z. Int J Biochem Cell Biol 43: 1090–1103. doi: 10.1016/j.biocel.2011.04.001 21501695
3. Dyson HJ, Wright PE, (2005) Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6: 197–208. doi: 10.1038/nrm1589 15738986
4. Whitford PC, Sanbonmatsu KY, Onuchic JN, (2012) Biomolecular dynamics: order-disorder transitions and energy landscapes. Rep Prog Phys 75: 076601. doi: 10.1088/0034-4885/75/7/076601 22790780
5. Cuchillo R, Michel J, (2012) Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem Soc Trans 40: 1004–1008. doi: 10.1042/BST20120086 22988855
6. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ, (2009) Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc. J Am Chem Soc 131: 7390–7401. doi: 10.1021/ja900616b 19432426
7. Michel J, Cuchillo R, (2012) The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc. PLoS ONE 7: e41070. doi: 10.1371/journal.pone.0041070 22815918
8. Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, et al. (2013) Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 23: 489–501. doi: 10.1016/j.ccr.2013.02.018 23597563
9. Fenton AW, (2013) Are all regions of folded proteins that undergo ligand-dependent order-disorder transitions targets for allosteric peptide mimetics? Biopolymers 100: 553–557. doi: 10.1002/bip.22239 23520021
10. Michel J, (2014) Current and emerging opportunities for molecular simulations in structure-based drug design. Phys Chem Chem Phys 16: 4465–4477. doi: 10.1039/c3cp54164a 24469595
11. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862–873. doi: 10.1038/nrc2763 19935675
12. Brown CJ, Cheok CF, Verma CS, Lane DP, (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32: 53–62. doi: 10.1016/j.tips.2010.11.004 21145600
13. Römer L, Klein C, Dehner A, Kessler H, Buchner J, (2006) p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts. Angew Chem Int Ed 45: 6440–6460. doi: 10.1002/anie.200600611 16983711
14. Honda R, Tanaka H, Yasuda H, (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25–27. 9450543
15. Momand J, Zambetti GP, Olson DC, George D, Levine AJ, (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245. doi: 10.1016/0092-8674(92)90644-R 1535557
16. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948–953. 8875929
17. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, et al. (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860. doi: 10.1038/362857a0 8479525
18. Showalter SA, Bruschweiler-Li L, Johnson E, Zhang F, Brüschweiler R, (2008) Quantitative Lid Dynamics of MDM2 Reveals Differential Ligand Binding Modes of the p53-Binding Cleft. J Am Chem Soc 130: 6472–6478. doi: 10.1021/ja800201j 18435534
19. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, et al. (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350: 587–598. 15953616
20. McCoy MA, Gesell JJ, Senior MM, Wyss DF, (2003) Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation. Proc Natl Acad Sci USA 100: 1645–1648. Available: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=12552135&retmode=ref&cmd=prlinks. 12552135
21. Anil B, Riedinger C, Endicott JA, Noble MEM, (2013) The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Cryst 69: 1358–1366.
22. Vassilev LT, (2004) In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science 303: 844–848. doi: 10.1126/science.1092472 14704432
23. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, et al. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48: 909–912. 15715460
24. Michelsen K, Jordan JB, Lewis J, Long AM, Yang E, et al. (2012) Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors. J Am Chem Soc 134: 17059–17067. doi: 10.1021/ja305839b 22991965
25. Hoe KK, Verma CS, Lane DP, (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 13: 217–236. doi: 10.1038/nrd4236 24577402
26. Shangary S, Wang S, (2009) Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy. Annu Rev Pharmacol Toxicol 49: 223–241. doi: 10.1146/annurev.pharmtox.48.113006.094723 18834305
27. Pierce LCT, Salomon-Ferrer R, Augusto F de Oliveira C, McCammon JA, Walker RC, (2012) Routine Access to Millisecond Time Scale Events with Accelerated Molecular Dynamics. J Chem Theory Comput 114: 2997–3002. doi: 10.1021/ct300284c
28. Markwick PRL, Pierce LCT, Goodin DB, McCammon JA, (2011) Adaptive Accelerated Molecular Dynamics (Ad-AMD) Revealing the Molecular Plasticity of P450cam. J Phys Chem Lett 2: 158–164. doi: 10.1021/jz101462n 21307966
29. Hamelberg D, Mongan J, McCammon JA, (2004) Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. J Chem Phys 120: 11919–11929. 15268227
30. Torrie GM, Valleau JP, (1977) Nonphysical sampling distributions in Monte Carlo free-energy estimation: Umbrella sampling. J Comput Phys 23: 187–199. doi: 10.1016/0021-9991(77)90121-8
31. Lee TS, Radak BK, Huang M, Wong K-Y, York DM, (2014) Roadmaps through Free Energy Landscapes Calculated Using the Multidimensional vFEP Approach. J Chem Theory Comput 10: 24–34. 24505217
32. Lee TS, Radak BK, Pabis A, York DM, (2013) A New Maximum Likelihood Approach for Free Energy Profile Construction from Molecular Simulations. J Chem Theory Comput 9: 153–164. doi: 10.1021/ct300703z 23457427
33. Best RB, Mittal J, (2011) Free-energy landscape of the GB1 hairpin in all-atom explicit solvent simulations with different force fields: Similarities and differences. Proteins 79: 1318–1328. doi: 10.1002/prot.22972 21322056
34. Best RB, (2012) Atomistic molecular simulations of protein folding. Curr Opin Struct Biol 22: 52–61. doi: 10.1016/j.sbi.2011.12.001 22257762
35. Joosten RP, Beek te TAH, Krieger E, Hekkelman ML, Hooft RWW, et al. (2011) A series of PDB related databases for everyday needs. Nucleic Acids Res 39: D411–D419. doi: 10.1093/nar/gkq1105 21071423
36. Kabsch W, Sander C, (1983) Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features—Kabsch—2004—Biopolymers—Wiley Online Library. Biopolymers 22: 2577–2637. 6667333
37. Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, José Marugán J, et al. (2006) Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design. Bioorg Med Chem Lett 16: 3310–3314. doi: 10.1016/j.bmcl.2006.03.055 16600594
38. Fry DC, Wartchow C, Graves B, Janson C, Lukacs C, et al. (2013) Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. ACS Med Chem Lett 4: 660–665. doi: 10.1021/ml400062c 24900726
39. Bista M, Wolf S, Khoury K, Kowalska K, Huang Y, et al. (2013) Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure 21: 2143–2151. doi: 10.1016/j.str.2013.09.006 24207125
40. Case DA, Darden TA, Cheatham TE, 3Simmerling C, Wang J, et al. (2012) AMBER12. Amber 12; University of California, San Francisco.
41. Li DW, Brüschweiler R, (2010) NMR-based protein potentials. Angew Chem Int Ed 49: 6778–6780. doi: 10.1002/anie.201001898 20715028
42. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 26: 114–114.
43. Jakalian A, Bush BL, Jack DB, (2000) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J Comput Chem 21: 132–146.
44. Jakalian A, Jack DB, Bayly CI, (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23: 1623–1641. 12395429
45. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926–935.
46. Aaqvist J, (1990) Ion-water interaction potentials derived from free energy perturbation simulations. J Phys Chem B 94: 8021–8024. doi: 10.1021/j100384a009
47. Niu RJ, Zheng Q-C, Zhang J-L, Zhang H-X, (2013) Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2–p53 interaction. J Mol Graph Model 46: 132–139. doi: 10.1016/j.jmgm.2013.10.005 24211465
48. Almerico AM, Tutone M, Pantano L, Lauria A, (2012) Molecular dynamics studies on Mdm2 complexes: An analysis of the inhibitor influence. Biochem Biophys Res Commun 424: 341–347. doi: 10.1016/j.bbrc.2012.06.138 22771796
49. Chen J, Wang J, Xu B, Zhu W, Li G, (2011) Insight into mechanism of small molecule inhibitors of the MDM2–p53 interaction: Molecular dynamics simulation and free energy analysis. J Mol Graph Model 30: 46–53. doi: 10.1016/j.jmgm.2011.06.003 21764342
50. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS, (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies. Cell Cycle 9: 1167–1181. doi: 10.4161/cc.9.6.11067 20190571
51. Michel J, Harker EA, Tirado-Rives J, Jorgensen WL, Schepartz A, (2009) In Silico Improvement of β 3-Peptide Inhibitors of p53•hDM2 and p53•hDMX. J Am Chem Soc 131: 6356–6357. doi: 10.1021/ja901478e 19415930
52. Dastidar SG, Lane DP, Verma CS, (2009) Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. BMC Bioinformatics 10 Suppl 15: S6. doi: 10.1186/1471-2105-10-S15-S6 19958516
53. Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS, (2007) Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study. Cell Cycle 6: 2604–2611. doi: 10.4161/cc.6.21.4923 17957142
54. Espinoza-Fonseca LM, Trujillo-Ferrara JG, (2006) Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers 83: 365–373. doi: 10.1002/bip.20566 16817233
55. Espinoza-Fonseca LM, Trujillo-Ferrara JG, (2006) Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: a molecular dynamics simulation study. Biochem Biophys Res Commun 343: 110–116. doi: 10.1016/j.bbrc.2006.02.129 16530164
56. Zhong H, Carlson HA, (2004) Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 58: 222–234. doi: 10.1002/prot.20275
57. Verkhivker GM, (2012) Simulating Molecular Mechanisms of the MDM2-Mediated Regulatory Interactions: A Conformational Selection Model of the MDM2 Lid Dynamics. PLoS ONE 7: e40897. doi: 10.1371/journal.pone.0040897 22815859
58. Dastidar SG, Raghunathan D, Nicholson J, Hupp TR, Lane DP, et al. (2011) Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: Simulations reveal complexities of modulation. Cell Cycle 10: 82–89. doi: 10.4161/cc.10.1.14345 21191186
59. Darden T, York D, Pedersen L, (1993) Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089–10092.
60. Ryckaert J-P, Ciccotti G, Berendsen HJC, (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23: 327–341.
61. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684–3690. doi: 10.1063/1.448118
62. Markwick PRL, McCammon JA, (2011) Studying functional dynamics in bio-molecules using accelerated molecular dynamics. Phys Chem Chem Phys 13: 20053–20065. doi: 10.1039/c1cp22100k 22015376
63. Hamelberg D, de Oliveira CAF, McCammon JA, (2007) Sampling of slow diffusive conformational transitions with accelerated molecular dynamics. J Chem Phys 127: 155102–155102–9. 17949218
64. Iannuzzi M, Laio A, Parrinello M, (2003) Efficient Exploration of Reactive Potential Energy Surfaces Using Car-Parrinello Molecular Dynamics. Phys Rev Lett 90: 238302. doi: 10.1103/PhysRevLett.90.238302 12857293
65. Laio A, Parrinello M, (2002) Escaping free-energy minima. Proc Natl Acad Sci USA 99: 12562–12566. doi: 10.1073/pnas.202427399 12271136
66. Wereszczynski J, McCammon JA, (2012) Accelerated molecular dynamics in computational drug design. Methods Mol Biol 819: 515–524. doi: 10.1007/978-1-61779-465-0_30 22183555
67. Pierce L, Salomon-Ferrer R, (2012) Routine Access to Millisecond Time Scale Events with Accelerated Molecular Dynamics—Journal of Chemical Theory and Computation (ACS Publications). J Chem Theory Comput 8: 2997–3002. 22984356
68. Bucher D, Grant BJ, Markwick PR, McCammon JA, (2011) Accessing a Hidden Conformation of the Maltose Binding Protein Using Accelerated Molecular Dynamics. PLoS Comput Biol 7: e1002034. doi: 10.1371/journal.pcbi.1002034 21533070
69. Wang Y, McCammon JA, (2012) Accelerated molecular dynamics: Theory, implementation and applications. AIP Conf Proc 1456: 165–172.
70. Shen T, Hamelberg D, (2008) A statistical analysis of the precision of reweighting-based simulations. J Chem Phys 129: 034103. doi: 10.1063/1.2944250 18647012
71. Sinko W, de Oliveira CAF, Pierce LCT, McCammon JA, (2012) Protecting High Energy Barriers: A New Equation to Regulate Boost Energy in Accelerated Molecular Dynamics Simulations. J Chem Theory Comput 8: 17–23. doi: 10.1021/ct200615k 22241967
72. Wereszczynski J, McCammon JA, (2010) Using Selectively Applied Accelerated Molecular Dynamics to Enhance Free Energy Calculations. J Chem Theory Comput 6: 3285–3292. doi: 10.1021/ct100322t 21072329
73. Fajer M, Hamelberg D, McCammon JA, (2008) Replica-Exchange Accelerated Molecular Dynamics (REXAMD) Applied to Thermodynamic Integration. J Chem Theory Comput 4: 1565–1569. doi: 10.1021/ct800250m 19461870
74. Doshi U, Hamelberg D, (2015) Towards fast, rigorous and efficient conformational sampling of biomolecules: Advances in accelerated molecular dynamics. Biochim Biophys Acta 1850: 878–888. Available: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25153688&retmode=ref&cmd=prlinks. doi: 10.1016/j.bbagen.2014.08.003 25153688
75. Ostmeyer J, Chakrapani S, Pan AC, Perozo E, Roux B, (2013) Recovery from slow inactivation in K+ channels is controlled by water molecules. Nature 501: 121–124. doi: 10.1038/nature12395 23892782
76. Kumar S, Rosenberg JM, Bouzida D, Swendsen RH, Kollman PA, (1992) The weighted histogram analysis method for free-energy calculations on biomolecules. I. The method. J Comput Chem 13: 1011–1021. doi: 10.1002/jcc.540130812
77. Delano WL, (2002) The PyMOL Molecular Graphics System. The PyMOL Molecular Graphics System, Version 1504; Schrödinger: Portland, OR, USA.
78. Humphrey W, Dalke A, Schulten K, (1996) VMD: Visual molecular dynamics. J Mol Graphics 14: 33–38. 8744570
79. Roe DR, Cheatham TE, III (2013) PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput 9: 3084–3095. doi: 10.1021/ct400341p
80. Miller BR, IIIMcGee TD, Jr.Swails JM, Homeyer N, Gohlke H, et al. (2012) MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J Chem Theory Comput 8: 3314–3321. doi: 10.1021/ct300418h